Description

Buy Palladone 32mg (Hydromorphone ER) Online

Buy palladone 32mg (Hydromorphone ER), Palladone 32mg Capsules (Hydromorphone ER) extended-release capsules are for oral use and contain hydromorphone hydrochloride, a mu-opioid.

Palladone 32mg Capsules (Hydromorphone ER) is 4,5α-epoxy-3-hydroxy-17-methlymorphinan-6-one hydrochloride.Palladone 32mg Capsules (Hydromorphone ER) is a white or almost white crystalline powder that is freely soluble in water, very slightly soluble in ethanol (96%), and practically insoluble in methylene chloride.

Qualitative and quantitative composition
Each capsule contains hydromorphone hydrochloride 2 mg, 4 mg, 8 mg, 16 mg, 24 mg, 32mg.

Clinical particulars
For the relief of severe pain in cancer.

Palladone 32mg Capsules (Hydromorphone ER) capsules are indicated in adults and children aged 12 years and above.

Posology and method of administration
Posology

Adults and children aged 12 years and above

Palladone 32mg Capsules (Hydromorphone ER) capsules should be used at 12-hourly intervals. The dosage is dependent upon the severity of the pain and the patient’s previous history of analgesic requirements. 4 mg of hydromorphone has an efficacy approximately equivalent to 30 mg of morphine sulphate given orally. A patient presenting with severe pain should normally be started on a dosage of 4 mg PALLADONE SR capsules 12-hourly. Increasing severity of pain may require increased dosage of hydromorphone to achieve the desired relief.

Elderly and patients with renal impairment

The elderly and patients with renal impairment should be dose titrated with PALLADONE SR capsules in order to achieve adequate analgesia. It should be noted, however, that these patients may require a lower dosage to achieve adequate analgesia.

Contraindications
Hydromorphone is contra-indicated in patients with known hypersensitivity to hydromorphone or other ingredients in the formulation.

It is also contra-indicated in respiratory depression with hypoxia or elevated carbon dioxide levels in the blood, coma, acute abdomen, hepatic impairment, paralytic ileus, concurrent administration of monoamine oxidase inhibitors or within 2 weeks of discontinuation of their use.

Concomitant use of Palladone 32mg Capsules (Hydromorphone ER)capsules and sedative medicines such as benzodiazepines or related drugs may result in sedation, respiratory depression, coma and death. Because of these risks, concomitant prescribing with these sedative medicines should be reserved for patients for whom alternative treatment options are not possible. If a decision is made to prescribe Palladone 32mg Capsules (Hydromorphone ER)capsules concomitantly with sedative medicines, the lowest effective dose should be used, and the duration of treatment should be as short as possible. The patients should be followed closely for signs and symptoms of respiratory depression and sedation. In this respect, it is strongly recommended to inform patients and their caregivers to be aware of these symptoms

Palladone 32mg Capsules (Hydromorphone ER)capsules are not recommended for pre-operative use or in the first 24 hours post-operatively. After this time they should be used with caution, particularly following abdominal surgery.

Palladone 32mg Capsules (Hydromorphone ER) capsules should not be used where there is the possibility of paralytic ileus occurring. Should paralytic ileus be suspected or occur during use, PALLADONE SR capsules should be discontinued.

Patients about to undergo cordotomy or other pain relieving surgical procedures should not receivePalladone 32mg Capsules (Hydromorphone ER)  capsules for 24 hours prior to surgery. If further treatment with Palladone 32mg Capsules (Hydromorphone ER) capsules is indicated, then the dosage should be adjusted to the new post-operative requirement.

PALLADONE-SR capsules are not recommended during pregnancy and labour due to impaired uterine contractility and the risk of neonatal respiratory depression. Prolonged use of hydromorphone during pregnancy can result in neonatal withdrawal syndrome.